Richard Banks, MD
Family Medicine · Fairfield, OHNPI 1245289529
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $248 and has fallen 50.5% since, to $123 in 2025.
Across 42 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$125
- Exact Sciences$119
- AbbVie$84
- Novo Nordisk$59
- Imperative Care, Inc$51
- Abbott$39
- plus $305 from 16 others
What the payments were for
- Food & beverage$783100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 6 | $125 |
| Exact Sciences | 6 | $119 |
| AbbVie | 5 | $84 |
| Novo Nordisk | 2 | $59 |
| Imperative Care, Inc | 1 | $51 |
| Abbott | 2 | $39 |
| Pfizer | 2 | $36 |
| Bayer | 2 | $31 |
| Lilly USA, LLC | 2 | $25 |
| Johnson & Johnson | 2 | $23 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Merck | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Medtronic | 1 | $18 |
| GSK | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Boehringer Ingelheim | 1 | $11 |
| Dynavax Technologies Corporation | 1 | $8 |
How this compares
$783 in reported general payments places this provider in the 60th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 45 | $75,427 |
| EliquisApixaban | 81 | $74,530 |
| XareltoRivaroxaban | 60 | $63,329 |
| OzempicSemaglutide | 45 | $60,738 |
| JardianceEmpagliflozin | 40 | $43,052 |
| JanuviaSitagliptin Phosphate | 20 | $32,603 |
| MyrbetriqMirabegron | 38 | $27,117 |
| FarxigaDapagliflozin Propanediol | 27 | $24,689 |
| MounjaroTirzepatide | 12 | $18,380 |
| TradjentaLinagliptin | 15 | $14,792 |
| InvokanaCanagliflozin | 17 | $14,451 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 97 | $12,529 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $8,332 |
| BelsomraSuvorexant | 12 | $7,007 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $6,700 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $25 | $93,80857 claims |
| Johnson & JohnsonXarelto, Invokana | $23 | $77,78077 claims |
| PfizerEliquis | $36 | $74,53081 claims |
| Novo NordiskOzempic | $59 | $60,73845 claims |
| Boehringer IngelheimJardiance, Tradjenta | $11 | $57,84555 claims |
| MerckJanuvia, Belsomra | $18 | $39,61032 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $27,11738 claims |
| AstraZenecaFarxiga | $14 | $24,68927 claims |
| GSKTrelegy Ellipta | $17 | $8,33214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Fairfield
- Kwabena OtengSpringdale$2M
- Brian BeesleyColumbus$1.4M
- Darshana PatelBeachwood$648K
- Thomas GraceFindlay$503K
- Susan RatayAshtabula$379K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
- Bradley EverlyMaumee$266K
- Tricia BedrickCuyahoga Falls$259K
- David NeidhardtLima$248K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.